StockNews.AI
FBRX
StockNews.AI
197 days

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

1. Forte Biosciences will present at two investor meetings in February and March. 2. CEO Paul Wagner will discuss FB102, their proprietary autoimmune therapy. 3. Presentations may enhance visibility and attract investor interest in FBRX.

5m saved
Insight
Article

FAQ

Why Bullish?

Investor meetings can lead to increased interest and stock price appreciation, similar to past occurrences in biotech firms after presentations.

How important is it?

Presentations can significantly influence stock performance by impacting market perception and interest in FBRX.

Why Short Term?

Immediate impact expected around the presentation dates; investor reaction can be swift.

Related Companies

FBRX

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--()--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.

Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY.

Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA.

About Forte

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Related News